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Abstract
Thrombosis is the cause of many cardiovascular syndromes and is a significant contributor to life-threatening diseases, such
as myocardial infarction and stroke. Thrombus targeted imaging agents have the capability to provide molecular
information about pathological clots, potentially improving detection, risk stratification, and therapy of thrombosis-related
diseases. Nanocarriers are a promising platform for the development of molecular imaging agents as they can be modified
to have external targeting ligands and internal functional cargo. In this work, we report the synthesis and use of chemically
functionalized bacteriophage MS2 capsids as biomolecule-based nanoparticles for fibrin imaging. The capsids were
modified using an oxidative coupling reaction, conjugating ,90 copies of a fibrin targeting peptide to the exterior of each
protein shell. The ability of the multivalent, targeted capsids to bind fibrin was first demonstrated by determining the
impact on thrombin-mediated clot formation. The modified capsids out-performed the free peptides and were shown to
inhibit clot formation at effective concentrations over ten-fold lower than the monomeric peptide alone. The installation of
near-infrared fluorophores on the interior surface of the capsids enabled optical detection of binding to fibrin clots. The
targeted capsids bound to fibrin, exhibiting higher signal-to-background than control, non-targeted MS2-based
nanoagents. The in vitro assessment of the capsids suggests that fibrin-targeted MS2 capsids could be used as delivery
agents to thrombi for diagnostic or therapeutic applications.
Citation: Obermeyer AC, Capehart SL, Jarman JB, Francis MB (2014) Multivalent Viral Capsids with Internal Cargo for Fibrin Imaging. PLOS ONE 9(6): e100678.
doi:10.1371/journal.pone.0100678
Editor: Pratul K. Agarwal, Oak Ridge National Laboratory, United States of America
Received October 28, 2013; Accepted May 30, 2014; Published June 24, 2014
Copyright:  2014 Obermeyer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: These studies were generously supported by the DOD Breast Cancer Research Program (BC061995). ACO and SLC were supported by graduate
research fellowships from the NSF. The UC Berkeley Chemical Biology Graduate Program (Training Grant 1 T32 GMO66698) is acknowledged for their support of
ACO. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: mbfrancis@berkeley.edu
Introduction
Cardiovascular disease is the leading cause of mortality in the
United States, currently accounting for one in three deaths overall
[1]. A significant contributor to the most life-threatening
cardiovascular diseases is thrombosis, which is the formation of
blood clots within the vascular system. These clots can, in turn,
occlude blood vessels and lead to ischemic syndromes including
myocardial infarction, stroke, pulmonary embolism, and deep vein
thrombosis. The noninvasive identification and molecular char-
acterization of thrombi could lead to improved detection of many
of these conditions, and could provide a useful means to monitor
the effectiveness of different treatment methods [2], [3], [4], [5],
[6]. A set of targeted agents that can specifically associate with
clots for the purpose of delivering PET radiotracers, MRI contrast
enhancement agents, or long wavelength responsive chromo-
phores is needed.
Nanomaterials could have several distinct advantages for the
targeting and imaging of molecular markers of thrombosis. Chief
among them is their large surface area, relative to small molecule
diagnostic agents, which could allow for the presentation of
multiple copies of targeting groups for enhanced binding avidity.
Nanoscale carriers can also be tailored to house multiple copies of
the reporter moieties, allowing greater signal-to-noise ratios to be
achieved. With these concepts in mind, many synthetic nanopar-
ticles have been developed for the purpose of targeted imaging [7],
including synthetic polymers [8], liposomes [9], dendrimers [10],
[11], and inorganic nanoparticles [12], [13]. Another approach to
preparing nanocarrier platforms relies on functionalized biomo-
lecular assemblies, such as viruses and virus-like particles (VLPs)
[14], [15], [16], [17], as well as mammalian protein cages
including heat shock cages [18], ferritins [19], [20], [21], and
vaults [22]. These protein-based nanoparticles have the natural
advantage of being monodisperse, nontoxic, and biodegradable.
Recent work has shown the utility of biomolecular assemblies,
such as VLPs, for targeted delivery to cancer [23], [24], [25] and
sites of inflammation [14], [18], [19], [26]. In these examples,
target binding peptide sequences have been incorporated directly
into the protein monomers [18], or synthetic targeting agents have
been installed using chemical bioconjugation techniques [25].
Although both strategies can be quite effective, the latter approach
has the advantage of increased modularity, and it can be used with
virtually any targeting agent, including aptamers [27], [28],
peptoids [29], [30], and engineered protein binders [31], [32].
Our group has previously used this strategy to functionalize
bacteriophage MS2 VLPs for targeted delivery [24].
Prior work on MS2-based delivery agents has shown that MS2
capsids can be heterologously expressed in E. coli, where they self-
assemble from 180 sequence-identical monomers to form 27 nm
diameter icosahedral capsids. These hollow MS2 capsids are stable
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toward a wide range of temperature, pH, and ionic strength
conditions, and are amenable to genetic mutation and sequence
insertions [33], [34], [35]. The assembled capsids contain 32 pores
that permit the diffusion of small molecules (, 2 nm) to the
interior of the VLPs. These pores, in conjunction with the
mutation of a residue on the interior surface of the capsid to a
uniquely reactive cysteine, have been used for the conjugation of
up to 180 maleimide-functionalized cargo molecules inside each
carrier [24]. The subsequent attachment of targeting groups to the
exterior surface has been accomplished with high efficiency by
targeting an unnatural amino acid, p-aminophenylalanine (pAF)
[34]. The side chain aniline group of this amino acid can be
modified with o-aminophenol-containing targeting groups using a
periodate-mediated oxidative coupling [36]. Other strategies for
preparing targeted MS2-based carriers have relied on the
attachment of synthetic peptides to exterior lysine residues [25],
[37].
Herein, we describe the use of this oxidative coupling strategy to
synthesize bacteriophage MS2-based VLPs that are conjugated to
synthetic peptide targeting groups. These structures also contain
multiple copies of near-infrared optical dyes for facile detection in
imaging experiments. The modified capsids were found to inhibit
fibrin clot formation at a concentration significantly lower than the
free peptide, demonstrating the benefits of using multivalent
nanoscale structures for target binding. Additionally, functiona-
lized MS2 capsids were used for the in vitro optical imaging of
fibrin clots. This in vitro work demonstrates the potential of MS2
VLPs for targeted molecular imaging of cardiovascular disease,
setting the stage for subsequent in vivo studies.
Results and Discussion
In this work, a peptide targeting group (GPR) with an affinity
for fibrin was chosen to create a thrombus targeted VLP [38]. The
GPR peptide was derived from the N-terminus of the a-chain of
fibrin (Gly-Pro-Arg), and was discovered to bind to a pocket in the
C-terminal region of the c-chain [39], [40]. The originally
discovered peptide was shown to inhibit thrombin-mediated fibrin
clotting by competitively binding to the fibrin polymerization
pocket. Subsequent optimization of the original peptide has
identified an extended peptide with improved fibrin-binding and
increased proteolytic resistance (Gly-Pro-Arg-Pro-Pro) [41]. This
updated peptide has been used to image pulmonary emboli in
swine and more recently has been attached to cross-linked iron
oxide particles for the ex vivo imaging of intravascular thrombi in
mice using fluorescence reflectance imaging [42], [43]. Although a
variety of other thrombus targeting strategies have proven effective
and could likely be used with similar results, the GPR-based
targeting strategy was chosen because this peptide has been used
successfully for in vivo imaging of thrombi [42], [43], [44], [45],
[46], [47].
The scheme for the synthesis of the fibrin targeted delivery
vehicle consisted of the selective modification of the interior of
MS2 with optical imaging agents, followed by the coupling of the
targeting peptide to the exterior surface (Figure 1a). A GPR
peptide bearing an o-aminophenol for coupling to MS2 was
prepared using solid phase peptide synthesis (Figure 1b) [48]. The
sequence Gly-Gly-Ser-Lys-Gly-Tyr was added to the peptide to
increase the spacing between the binding residues and the capsid,
as well as provide a functional handle for modification (Tyr). For
peptide samples used in optical imaging experiments, a cysteine
residue was also included at the C-terminus to allow modification
with the same near-infrared maleimide dye that was introduced in
the VLPs (see below). This allowed the binding behavior of the free
peptides and the peptide-MS2 conjugates to be compared directly.
A non-binding peptide analog was also synthesized as a negative
control. It has been reported that a single amino acid change in
the GPR peptide (Arg to Ser) drastically decreases its affinity for
fibrin [38]. This peptide (GPS) was used as a negative control both
as a free peptide and after conjugation to MS2 (GPS-MS2).
To attach the peptide targeting groups to the MS2 capsids, we
used a previously described double mutant of the capsid protein,
Thr19pAF/Asn87Cys (T19pAF/N87C) and a recently reported
NaIO4-mediated oxidative coupling of anilines and o-aminophe-
nols (Figure 1a) [24], [36]. The aniline functionality was
introduced onto the exterior surface of the capsids using the
amber stop codon suppression method developed by the Schultz
group [49], [50]. The o-aminophenol functionality was then
incorporated into the peptide targeting group by chemically
modifying a tyrosine residue after synthesis on the solid phase
using standard Fmoc chemistry [48]. Removal of the side-chain
protecting groups, azo coupling, and subsequent reduction with
Na2S2O4 afforded the desired o-aminophenol-containing peptides
(Figure 1c). The peptide modification was confirmed by mass
spectrometry (MS), and the site of modification was verified
through MS/MS analysis (Figures S1, S2, S3). The ability of the
modified peptides to participate in the periodate-mediated
oxidative coupling was confirmed by reacting the o-aminophe-
nol-containing peptides with 1 equiv of p-toluidine and 10 equiv of
Figure 1. Design of a viral capsid-based targeting system. (a) A
scheme is shown for the synthesis of multivalent viral capsids for fibrin
imaging. (b) Peptides used for attachment to MS2 or binding to fibrin.
Peptides with a cysteine at the C-terminus were modified with a
fluorescent dye and used for fibrin binding, while peptides with a C-
terminal tyrosine were coupled to MS2 and tested for fibrin clotting
inhibition. (c) Scheme for o-aminophenol peptide synthesis. The C-
terminal tyrosine residue was coupled to 4-nitrobenzenediazonium
tetrafluoroborate. The azo peptide was then cleaved from the resin and
reduced to the o-aminophenol by sodium dithionite.
doi:10.1371/journal.pone.0100678.g001
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NaIO4, followed by MS characterization (Figure S4). The o-
aminophenol containing peptides were then coupled to aniline-
containing MS2 capsids using the periodate-mediated oxidative
coupling shown in Figure 2a. This bioconjugation strategy was
chosen because it is fast, chemoselective and has been used
successfully on complex biomolecular assemblies. By altering the
reaction time from 30 s to 10 min and the number of peptide
equivalents from 1 to 40, the extent of peptide labeling could be
varied from 18 to 150 peptides/capsid (Figure S5a,b). The
periodate-mediated coupling was optimized to install approxi-
mately 90 peptides on the surface of each capsid in 5 min,
corresponding to ,50% modification of MS2 monomers as
determined using optical densitometry of SDS-PAGE gels
(Figure 2b, Figure S6). This level of modification was achieved
using 10 equiv of the o-aminophenol peptide and 100 equiv of
NaIO4. No coupling was observed for control reactions with
capsids lacking the pAF groups (both wt-MS2 and T19Y MS2),
confirming the chemoselectivity of the method (Figure S5c). The
coupling reactions were terminated by removal of the NaIO4 via
gel filtration through Nap 5 Sephadex columns. After modifica-
tion, the assembly state of the capsids was confirmed by
transmission electron microscopy (TEM), dynamic light scattering
(DLS), and size-exclusion chromatography (SEC, Figure 2c-e,
Figure S7). Unmodified MS2 capsids were measured to have a
diameter of 27.761.1 nm using DLS, while the modified capsids
were determined to have diameters of 29.160.2 nm and
28.060.6 nm for GPR-MS2 and GPS-MS2, respectively. DLS
also confirmed that the capsids had a normal size distribution [24],
[51].
The ability of the peptides to bind to fibrin, both before and
after conjugation to MS2, was first verified through the use of a
clotting inhibition assay (Figure 3a). Agents capable of binding to
fibrin were expected to slow thrombin-mediated clotting because
the GPR peptide competitively binds to fibrin at the site necessary
for initial fibrin aggregation. Fibrin clotting times in the presence
of each of the agents were determined by measuring the extent of
light scattering at 350 nm [52]. In agreement with previously
published reports, free GPR was found to inhibit thrombin
induced clotting at high concentrations ($300 mM), but free GPS
did not do so at any of the concentrations assayed (Figure S8) [38],
[42]. Unmodified MS2 capsids and capsids labeled with ,50%
peptide (GPR-MS2 and GPS-MS2) were also assayed for their
ability to inhibit clotting. At 222 nM MS2 capsid (40 mM in MS2
monomer and ,20 mM in peptide), GPR-MS2 slowed aggrega-
tion, while none of the other agents showed an effect (Figure 3b).
Clotting times more than doubled when treated with GPR-MS2
(51629 min), whereas they remained unchanged when treated
with free GPR (18613 min), free GPS (1366 min), MS2
(1669 min) or GPS-MS2 (1666 min). GPR-MS2 slowed fibrin
polymerization at a peptide concentration approximately ten-fold
less than that observed for the free peptide. We found that the
multivalent display of the binding moiety resulted in increased
avidity of the targeting peptide. While others have observed
varying effects with a multivalent display of similar peptides
(GPRP), perhaps both the spacing between the peptides and the
size of the multivalent object play a role in the interaction of
fibrin/fibrinogen with these peptides in multivalent displays [53],
[54]. Others have observed similar increases in avidity with
different multivalent objects [25], [55], [56], [57], [58].
The potential for MS2 VLPs to image fibrous clots was also
tested in vitro. The introduction of a reactive cysteine to the interior
surface of MS2 allowed for the conjugation of maleimide
functionalized imaging agents. Previous work has shown that the
capsids can be labeled with fluorescent dyes for optical imaging,
Gd3+ and 129Xe for MRI, and 64Cu for PET using this strategy
[24], [59], [60], [61]. For this work, MS2 capsids were modified
with ,60 copies of Alexa Fluor 680 to create near-infrared optical
imaging agents. GPR or GPS peptides were then installed on the
exterior surface using the oxidative coupling strategy described
above [36]. This resulted in ,45–55% labeling for GPR-MS2
(,100 peptides/capsid) and GPS-MS2 (,80 peptides/capsid).
To prepare well-defined clots for use in the binding assays,
purified bovine fibrinogen was added to a series of Eppendorf
tubes. Thrombin and CaCl2 were added to induce aggregation.
After 1 h, the MS2-based agents were added to the fibrin clots at a
capsid concentration of 111 nM (20 mM in MS2 monomer,
approximately 10 mM in peptide). After 3 h of exposure at room
temperature, the clots were rinsed three times with TBS and then
transferred to a 96-well plate. The samples were imaged with an
optical scanner using the 700 nm channel (Figure 3c). Clots
treated with the fibrin-targeted MS2 capsids (GPR-MS2) showed
greater signal than clots incubated with control agents (GPS-MS2
and MS2, Figure 3d). The signal intensity was normalized to the
unmodified MS2 capsids to allow for comparison between
experiments. While the MS2 capsids showed some background
Figure 2. Characterization of MS2 conjugates. (a) The periodate-
mediated oxidative coupling reaction takes place between o-amino-
phenol peptides and aniline containing MS2 capsids. (b) Alexa Fluor 680
and peptide-MS2 conjugates were analyzed by SDS-PAGE, with
visualization of fluorescent (Figure S5) and Coomassie-stained bands
(shown). Lanes 1–3 show disassembled MS2 monomers labeled with
Alexa Fluor 680. In lane 2, the GPR peptide was added and in lane 3 the
GPS peptide was added. The upper bands represent the fraction of the
MS2 monomers conjugated to the peptides. (c) Transmission electron
microscopy, (d) dynamic light scattering, and (e) size-exclusion
chromatography (fluorescence: lex = 280 nm, lem = 330 nm) of MS2,
GPR-MS2, and GPS-MS2 confirmed that the capsids remained intact
after modification. Wide-field TEM images appear in Figure S7.
doi:10.1371/journal.pone.0100678.g002
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sticking, conjugation of the non-binding peptide to the exterior
(GPS-MS2) greatly diminished the binding of the capsids. When
the fibrin binding peptide was displayed on the exterior of MS2
(GPR-MS2), however, the capsids showed some enhanced binding
relative to both the unmodified (MS2) and non-binding (GPS-
MS2) capsids. The binding of the targeted capsid (GPR-MS2) was
also evaluated in serum to mimic the complex milieu found in vivo.
The fibrin binding of the targeted capsid was not inhibited by the
addition of serum (Figure S9). The ability to bind at such low
concentrations parallels results using single-chain antibody frag-
ments, antibodies and other peptides [45], [46], [47], [62], [63].
However, in this case, significant amounts of imaging cargo can be
simultaneously delivered for improved signal-to-noise ratios.
The free peptides were also labeled with Alexa Fluor 680 and
tested for comparison. Before use, the modified peptides were
HPLC purified and characterized by MS and MS/MS analysis
(Figures S10, S11, S12, S13). The binding of the GPR and GPS
peptides was compared to that of the Alexa Fluor 680 dye at
concentrations ranging from 0.1 to 10 mM (Figure S14). At all
concentrations tested, the peptides and dye non-specifically bound
the fibrin clots. Additionally, the quantified signal-to-background
ratio revealed that the free dye associated with the clots as well as,
or better than, the free peptides. The binding of the free peptides
was expected to be drastically perturbed by the Alexa Fluor 680
dye because the unlabeled peptides and dye have similar
molecular weights. This did not affect the MS2-based agents,
however, because the optical imaging agent was sequestered inside
the capsid where it could not interact with fibrin.
Conclusion
In this work, we describe the synthesis of a new VLP for the
targeted imaging of thrombi. This study highlights the use of
multivalent scaffolds to achieve increased binding and the use of
an efficient oxidative coupling strategy for the installation of many
copies of a given functional group in a short period of time. The
MS2-based delivery vehicle was shown to bind fibrin, a key
molecular target in blood clots, with greater efficiency than that of
free peptides evaluated at the same concentration. The multivalent
display of the peptide on the MS2 capsid improved the ability of
the GPR peptide to inhibit thrombin-mediated clotting. The
attachment of near-infrared dyes allowed for in vitro optical
detection of fibrin binding. The modular synthesis of these agents
allows for the facile modification of GPR-MS2 with MRI, PET, or
optical imaging probes. The attachment of these other imaging
agents will allow for the evaluation of these agents in future in vivo
imaging studies.
Materials and Methods
General procedures and materials
Unless otherwise noted, the chemicals and solvents used were of
analytical grade and were used as received from commercial
sources. Water (dd-H2O) used as reaction solvent and in biological
procedures was deionized using a Barnstead NANOpure purifi-
cation system (ThermoFisher, Waltham, MA).
Mass Spectrometry
Matrix assisted laser desorption-ionization time-of-flight mass
spectrometry (MALDI-TOF MS) was performed on a Voyager-
DE system (PerSeptive Biosystems, USA) and data were analyzed
using Data Explorer software. Peptide samples were co-crystallized
with a-cyano-4-hydroxycinnamic acid in 1:1 acetonitrile (MeCN)
to H2O with 0.1% trifluoroacetic acid (TFA). Electrospray
ionization mass spectrometry (ESI-MS) of peptides was performed
using an Agilent 1100 series LC pump outfitted with either an
Agilent 6224 Time-of-Flight (TOF) LC/MS system or an API
150EX system (Applied Biosystems, USA) equipped with a
Turbospray ion source. LC-ESI-MS of proteins and tandem mass
spectrometry (MS/MS) of peptides were obtained from the UC
Berkeley QB3/Chemistry Mass Spectrometry Facility. Protein
bioconjugates were analyzed using an Agilent 1200 series liquid
chromatograph (Agilent Technologies, USA) that was connected
in-line with an LTQ Orbitrap XL hybrid mass spectrometer
equipped with an Ion Max electrospray ionization source (ESI;
Figure 3. Fibrin targeting with GPR-MS2 conjugates. (a) Five
different agents were tested for fibrin binding properties. (b) Binding to
fibrin monomers was confirmed with a clotting inhibition assay.
Clotting times are plotted as the average of several trials (n = 4-6),
shown with the standard error. The grey bar indicates the 95%
confidence interval for the water control. At a concentration of 20 mM
peptide, (222 nM MS2 capsid), only GPR-MS2 increased the thrombin
induced clotting time of fibrin (Welch’s t-test, p,0.05). (c) A
representative near-infrared fluorescence image of fibrin clots in a 96-
well plate indicated the in vitro binding of agents to the clots. (d)
Binding was quantified, showing that the differences in relative spot
intensity (normalized to the MS2 capsid intensity) between the agents
were statistically significant (*p,0.05; **p,0.01). Normalized intensities
are shown with the standard error.
doi:10.1371/journal.pone.0100678.g003
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Thermo Fisher Scientific, Waltham, MA). MS/MS analysis was
accomplished with a using a Waters nanoAcquity ultra perfor-
mance liquid chromatograph (UPLC)/quadrupole time-of-flight
(Q-TOF) Premier instrument.
High Performance Liquid Chromatography
HPLC was performed on Agilent 1100 Series HPLC Systems
(Agilent Technologies, USA). Sample analysis for all HPLC
experiments was achieved with an inline diode array detector
(DAD) and inline fluorescence detector (FLD). Analytical and
preparative reverse-phase HPLC of peptides and proteins was
accomplished using a C18 stationary phase and a MeCN/H2O
with 0.1% TFA gradient mobile phase. Analytical size exclusion
chromatography of peptides and proteins was accomplished using
a BioSep 4000S stationary phase with isocratic flow of aqueous
buffer (10 mM phosphate buffer, pH 7.2).
Gel Analyses
For protein analysis, sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) was carried out on a Mini-Protean
apparatus (Bio-Rad, Hercules, CA), using a 10–20% precast linear
gradient polyacrylamide gel (Bio-Rad). The sample and electrode
buffers were prepared according to Laemmli [64]. All protein
electrophoresis samples were heated for 5–10 min at 95uC in the
presence of 1,4-dithiothreitol (DTT) to ensure reduction of
disulfide bonds. Gels were run for 75–90 minutes at 120 V to
separate the bands. Commercially available markers (Bio-Rad)
were applied to at least one lane of each gel for assignment of
apparent molecular masses. Visualization of protein bands was
accomplished by staining with Coomassie Brilliant Blue R-250
(Bio-Rad). For fluorescent protein conjugates, visualization was
accomplished on a Typhoon 9410 variable mode imager
(Amersham Biosciences) courtesy of Prof. Carolyn Bertozzi prior
to gel staining. Coomasie stained protein gels were imaged on an
EpiChem3 Darkroom system (UVP, USA).
Dynamic Light Scattering
DLS measurements were obtained using a Malvern Instruments
Zetasizer Nano ZS, courtesy of Prof. Jean Fre´chet. Data plots were
calculated from an average of three measurements, each of which
consisted of 12 runs of 45 s each. Measurement data are presented
as a volume plot, which weights larger dimensions by a factor of
103 more than smaller dimensions. Samples were measured in
10 mM phosphate buffer, pH 7.2.
Transmission Electron Microscopy
TEM images were obtained at the UC Berkeley Electron
Microscope Lab (www.em-lab.berkeley.edu) using a FEI Tecnai
12 transmission electron microscope with 120 kV accelerating
voltage. Protein samples were prepared for TEM analysis by
pipetting 5 mL of the samples onto Formvar-coated copper mesh
grids (400 mesh, Ted Pella, Redding, CA), after 3 min of
equilibration the samples were then wicked with filter paper.
The samples were then rinsed with dd-H2O. Subsequently, the
grids were exposed to 8 mL of a 1% (w/v) aqueous solution of
uranyl acetate for 90 s as a negative stain. After excess stain was
removed, the grids were allowed to dry in air.
General procedure for solid-phase peptide synthesis
Peptides were synthesized using standard Fmoc-based chemistry
on Tentagel S-OH resin (Advanced ChemTech, Louisville, KY).
The side chain protecting groups used were: Arg(Pbf), Cys(Trt),
Lys(Boc), Ser(tBu), Tyr(tBu). The C-terminal amino acid (10
equiv) was preactivated at 0uC with 5 equivalents of diisopro-
pylcarbodiimide (DIC) and then coupled to the resin with 0.1
equivalents of N,N-dimethylaminopyridine (DMAP) as a catalyst.
Deprotection of the Fmoc groups was performed with a 20 min
incubation in a 20% v/v piperidine in dimethylformamide (DMF)
solution. Coupling reactions were carried out using 20 equivalents
of amino acid with 10 equivalents of 2-(6-chloro-1-H-benzotria-
zole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate
(HCTU) [48] and 20 equivalents of N,N-diisopropylethylamine
(DIPEA) in DMF for 20 min. Side-chain deprotection was
accomplished using a 1–2 h incubation with either a 95:2.5:2.5
ratio of TFA to H2O to triisopropylsilane (TIPS) (peptides without
cysteine) or a 90:5:2.5:2.5 ratio of TFA to phenol to H2O to TIPS
(peptides containing cysteine). Peptides were cleaved from the
resin by a 30–45 min incubation with a 100 mM sodium
hydroxide solution. The resulting basic solution was neutralized
with 100 mM phosphate buffer, pH 6.5.
General procedure for azo coupling to peptides
To a portion of resin-bound peptide (appx. 20 mg) in 900 mL of
100 mM phosphate buffer, pH 9.0 was added 100 mL of a
saturated solution of 4-nitrobenzenediazonium tetrafluoroborate
(300 mM, Sigma-Aldrich) in MeCN at 4uC. After rotation for
30 min at 4uC, the resin was rinsed with MeCN and DMF until no
color remained in solution. The peptides were then cleaved from
the resin, and the modification was confirmed by MALDI-TOF
MS (Figures S1–S2).
General procedure for dithionite reduction of azo
peptides
To a solution of azo-modified peptide (appx. 1 mM) in 100 mM
phosphate buffer, pH 6.5 was added an equal volume of a freshly
prepared solution of sodium dithionite (115 mM) in 100 mM
phosphate buffer, pH 7.2. After 10 min, the solution was applied
to a C18 Sep-Pak pre-conditioned with methanol then 0.1%
aqueous TFA. After washing with aqueous 0.1% TFA and 5%
MeCN in aqueous 0.1% TFA, the peptide was eluted with MeCN.
After removing the MeCN under reduced pressure the solid
peptide was dissolved in 100 mL of 10 mM phosphate buffer,
pH 6.5. The o-aminophenol peptide was characterized by
MALDI-TOF or LC-ESI MS (Figures S1–S2) and stored at
4uC. The site of modification was confirmed for the GPR peptide
by MS/MS analysis (Figure S3).
General procedure for maleimide modification of
peptides
To a 1.75 mM solution of cleaved peptide in 10 mM phosphate
buffer, pH 8.0 was added 1.1 equivalents of tris(2-carboxyethyl)-
phosphine hydrochloride (0.5 M solution, pH 7.0). After 15 min,
0.6 equivalents of maleimide (Alexa Fluor 680 C2-maleimide,
20 mM in DMSO) was added and the solution was briefly
vortexed. The peptides were incubated in the dark at room
temperature overnight. The peptides were then purified by HPLC
using a C18 Gemini column (5 micron, 25067.8 mm, Phenom-
enex, Torrance, CA). The purified peptides were characterized by
LC-ESI-MS and MS/MS (Figures S9–12).
Expression and Purification of T19pAF N87C MS2
The protein was expressed and purified following a previously
published protocol [34]. After purification, approximately 10 mg
of protein were obtained per L of culture.
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General procedure for oxidative coupling of
o-aminophenol peptides to pAF MS2
To a solution of T19pAF N87C MS2 (10 mM) in 10 mM
phosphate buffer, pH 6.5 was added 5–10 equivalents of o-
aminophenol peptide (50–100 mM). The solution was briefly
vortexed and then 10 equivalents (relative to the o-aminophenol)
of sodium periodate was added. After 5 min, the reaction was
purified on a Nap 5 Sephadex size exclusion column (GE
Healthcare) according to the manufacturer’s instructions and
eluted in 10 mM phosphate buffer, pH 7.2. Any remaining
periodate and free peptide were removed using a 0.5 mL
centrifugal filter with a molecular weight cut off (MWCO) of
100 kDa (Millipore). The samples were concentrated to 50 mL and
then diluted 10-fold with 10 mM phosphate buffer, pH 7.2. This
process was repeated 5–10 times depending on the concentration
of peptide used. Modification was monitored by SDS-PAGE and
quantified using optical densitometry (Figures S5–6).
General procedure for dual modification of T19pAF N87C
MS2
Dual modification always started with maleimide modification
of the interior cysteine. A solution of T19pAF N87C MS2
(100 mM) in 10 mM phosphate buffer, pH 7.2 was incubated with
1 equivalent of Alexa Fluor 680 C2-maleimide (38 mM in DMSO)
for 2 h. Unreacted dye was removed with a Nap 10 Sephadex size
exclusion column (GE Healthcare) and by repeated centrifugal
filtration against a 100 kDa MWCO membrane. Exterior
modification with an o-aminophenol peptide was performed as
described in the main text and as described above. Modification
was monitored by SDS-PAGE (Figure 2).
Inhibition of fibrin clot formation
Bovine fibrinogen ($75% clottable, Sigma Aldrich, USA) was
dissolved in 0.9% saline solution at 37uC at a concentration of
12 mg/mL. Bovine thrombin (100 U/mL) was dissolved in
phosphate buffered saline (PBS) and added into wells of a 96-
well polystyrene half area plate (Costar, Corning, NY) to a final
concentration of 0.25 U/well. Assayed agents (H2O (control),
GPR peptide, GPS peptide, MS2, GPR-MS2, and GPS-MS2)
were added to the wells (72.5 mL/well, n = 4–6) to a final
concentration of 20 mM peptide (40 mM in MS2 monomer for
MS2, GPR-MS2, and GPS-MS2 for an effective peptide
concentration of 20 mM and capsid concentration of 222 nM).
Immediately preceding absorbance measurements, 25 mL of the
fibrinogen solution was added to each well (0.3 mg/well). The
absorbance at 350 nm was monitored once a minute for 75 min
using a SpectraMax M3 microplate reader (Molecular Devices,
Sunnyvale, CA), courtesy of Prof. Carolyn Bertozzi. Additional
concentrations of peptide (10 mM to 1.7 mM) were evaluated for
their ability to inhibit fibrin clot formation in a similar manner
(Figure S8). The clotting time was determined to be the time at
which the absorbance first approached the horizontal asymptote.
Statistical significance was evaluated by a one-tailed Student’s t-
test with unequal variance (n = 4–6).
Binding to fibrin clots
Bovine fibrinogen ($75% clottable, Sigma Aldrich, USA) was
dissolved in 50 mM Tris, pH 7.4, 150 mM sodium chloride (TBS)
and dialyzed against TBS with 5 mM sodium citrate (TBS-citrate).
The resulting fibrinogen solution was adjusted to 4 mg/mL by
measuring the absorbance at 280 nm (a 1 mg/mL fibrinogen
solution has an absorbance of 1.512 OD units) [65]. The
fibrinogen solution (50 mL) was aliquoted into Eppendorf tubes.
Subsequently, calcium chloride (10 mL of a 70 mM solution) and
0.4 U of bovine thrombin (10 U/mL in TBS) were added to each
tube to initiate clotting. After incubation at room temperature for
1 h, 100 mL of Alexa Fluor 680 labeled agent (MS2, GPR-MS2 or
GPS-MS2) was added to each clot (n = 3, with 4–6 replicates per
experiment) for a final concentration of 20 mM MS2 monomer
(111 nM MS2 capsid and approximately 10 mM peptide). The
agents were allowed to bind for 3 h at room temperature and then
the clots were washed 3 times with 200 mL TBS. The clots were
transferred to a 96-well polystyrene plate (Costar, Corning, NY)
and centrifuged at 4000 rpm for 10 min. The plate was imaged
using an Odyssey CLx infrared imaging system (Li-Cor, Lincoln,
NE) courtesy of Prof. Jay Groves. The binding of GPR-MS2 was
also evaluated in fetal bovine serum (FBS) following the protocol
outlined above (8 replicates). The resulting images were quantified
using ImageJ 1.42q software (NIH) using the Microarray Profile
plugin to select regions-of-interest. The image was pseudo-colored
in ImageJ. Additionally, AlexaFluor 680 labeled peptide and free
AlexaFluor 680 C2-maleimide (10, 1, and 0.1 mM) were tested for
their binding to fibrin clots (Figure S14). Statistical significance was
evaluated by a one-tailed Student’s t-test with unequal variance
(n = 3, with 4-6 replicates per experiment).
Supporting Information
Figure S1 Conversion of GPR peptide C-terminal
tyrosine to an o-aminophenol. MALDI-TOF MS was used
to monitor the modification of (a) the unmodified peptide to (b) the
azo-peptide with 4-nitrobenzenediazonium tetrafluoroborate, and
then subsequent sodium dithionite reduction to (c) the o-
aminophenol peptide.
(TIFF)
Figure S2 Conversion of GPS peptide C-terminal tyro-
sine to an o-aminophenol. MALDI-TOF MS was used to
monitor the modification of (a) the unmodified peptide to (b) the
azo-peptide with 4-nitrobenzenediazonium tetrafluoroborate, and
then subsequent sodium dithionite reduction to (c) the o-
aminophenol peptide.
(TIFF)
Figure S3 MS/MS analysis of o-aminophenol modified
GPR peptide. (a) MS/MS of the GPR peptide and (b) fragments
shown in blue are y ions (modified fragments), fragments shown in
red are b ions (unmodified fragments), fragments shown in green
are imminium ions (both modified and unmodified fragments),
and fragments shown in purple are a ions (unmodified fragments).
Products of neutral loss of molecules of water or ammonia are
denoted by asterisks. The analysis is consistent with the
modification of the C-terminal tyrosine.
(TIFF)
Figure S4 Oxidative coupling to o-aminophenol con-
taining peptides. (a) The GPR peptide was coupled to 1 equiv
of p-toluidine in 5 min in the presence of 10 equiv of NaIO4. The
reaction was quenched with tris(2-carboxyethyl)phosphine hydro-
chloride (0.5 M solution, pH 7.0) and the mass of the coupled
peptide was confirmed by ESI-MS. (b) The GPS peptide was
similarly coupled to p-toluidine and the product was confirmed by
ESI-MS.
(TIFF)
Figure S5 Oxidative coupling optimization screen with
GPR peptide. (a) Coupling of varying concentrations of GPR
peptide with 25 mM T19pAF N87C MS2 in the presence of 1 mM
sodium periodate in 10 mM phosphate buffer, pH 7.2 for 10 min.
Varying the peptide concentration allowed for control over the
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level of modification. The secondary modification is presumed to
be due to a second addition of the o-aminophenol to the exterior
aniline as this has occasionally been observed with small
molecules. (b) A time course experiment with 25 mM T19pAF
N87C MS2, 100 mM GPR peptide, and 1 mM sodium periodate
in 10 mM phosphate buffer, pH 7.2. Each time point was
quenched by the addition of 5 mL of loading buffer. The reaction
reached maximum conversion after 2.5–5 min. (c) Negative
controls confirm the specificity of the reaction for the aniline
side-chain. Additionally, both coupling partners and periodate
were necessary for modification to be observed.
(TIFF)
Figure S6 Alexa Fluor 680 and peptide-MS2 conjugates were
analyzed by SDS-PAGE, with visualization of fluorescent and
Coomassie-stained bands. Lanes 1-3 show disassembled MS2
monomers labeled with Alexa Fluor 680. In lane 2, the GPR
peptide was added and in lane 3 the GPS peptide was added. The
upper bands represent the fraction of the MS2 monomers
conjugated to the peptides. (a) Shows the full gel image and (b)
shows a zoomed in view of the region of interest. Unmarked lanes
contain either recombinant prestained protein standards (Bio-Rad)
or the negative controls seen in Figure S5c. The protein standards
were visible under Coomassie staining conditions, but the
standards were not fluorescent so they were not observed in the
fluorescence image. (c) Another gel shows the shift observed for
Alexa Fluor 680 labeled capsids as well as the additional shift
observed after subsequent conjugation of peptides. Lane 4 shows
unmodified MS2 monomers and lane 5 shows Alexa Fluor 680
labeled monomers. The Alexa Fluor 680 labeled MS2 was
subsequently modified with peptides, and lanes 6 and 7 show the
addition of the GPR and GPS peptides, respectively.
(TIFF)
Figure S7 Wide-field TEM images of (a) T19pAF N87C MS2,
(b) GPR-MS2 (,33% modified, ,60 peptides/capsid), and (c)
GPS-MS2 (,45% modified, ,80 peptides/capsid) revealed that
the capsids remained intact after the oxidative coupling of peptides
to the exterior surface. The observed debris may be due to the age
of the capsids or the TEM grids; images taken shortly after
purification showed little debris.
(TIFF)
Figure S8 Inhibition of thrombin induced fibrin clotting
with varying concentrations of free GPR and GPS
peptides. Only at high concentrations ($ , 300 mM) of GPR
peptide was an effect observed. The concentrations used in
Figure 3b of the main text (10–60 mM, starred on graph) showed
no effect for either peptide.
(TIFF)
Figure S9 The binding of GPR-MS2 (20 mM MS2 monomer,
111 nM MS2 capsid, and ,10 mM peptide) in fetal bovine serum
(FBS) was compared to binding in Tris buffered saline (TBS). The
addition of serum did not inhibit binding of the targeted capsids.
(TIFF)
Figure S10 Modification of GPR peptide C-terminal
cysteine with Alexa Fluor 680 C2-maleimide. ESI-MS
confirmed the mass of (a) the unmodified peptide and showed the
mass of (b) Alexa Fluor 680 modification of the GPR peptide.
(TIFF)
Figure S11 Modification of GPS peptide C-terminal
cysteine with Alexa Fluor 680 C2-maleimide. ESI-MS
confirmed the mass of (a) the unmodified peptide and showed the
mass of (b) Alexa Fluor 680 modification of the GPS peptide.
(TIFF)
Figure S12 MS/MS analysis of Alexa Fluor 680 modified
peptide. (a) MS/MS of the GPR peptide and (b) fragments
shown in blue are y ions (modified fragments), fragments shown in
red are b ions (unmodified fragments), fragments shown in green
are imminium ions (both modified and unmodified fragments),
and fragments shown in purple are a ions (unmodified fragments).
The analysis is consistent with the modification of the C-terminal
cysteine.
(TIFF)
Figure S13 MS/MS analysis of Alexa Fluor 680 modified
GPS peptide. (a) MS/MS of the GPS peptide and (b) fragments
shown in blue are y ions (modified fragments), fragments shown in
red are b ions (unmodified fragments), fragments shown in green
are imminium ions (both modified and unmodified fragments),
and fragments shown in purple are a ions (unmodified fragments).
The analysis is consistent with the modification of the C-terminal
cysteine.
(TIFF)
Figure S14 Alexa Fluor 680 labeled peptides and Alexa Fluor
680 were assayed for their binding to fibrin clots. At all
concentrations tested (10, 1, and 0.1 mM) the two peptides showed
no difference in binding. Additionally, the free dye associated non-
specifically to the clots as well as, or better than, the peptides
modified with the fluorescent dye. The average signal-to-
background (n= 6) is shown with the standard error.
(TIFF)
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